Increasing Occurrence of Diabetes to Drive Europe Smart Insulin Pens Market at a CAGR of Around 12.21% During 2025-30

• Overview
• Table of Content
• Research Methodology
• Download Free Sample

The Europe Smart Insulin Pens Market size was valued at around USD 109 million in 2024 and is projected to reach USD 223 million by 2030. Along with this, the market is estimated to grow at a CAGR of around 12.21% during the forecast period, i.e., 2025-30, cites MarkNtel Advisors in the recent research report. The rise in the number of diabetic patients and advanced innovations are some of the key factors impacting the market growth of smart insulin pens in Europe. As per the IDF Atlas, the diabetic patient's prevalence amongst adults in the region has significantly increased, with projections in 2021 to be 7.0% and anticipated to rise to 8.0% by 2030. Such enhanced diabetic prevalence rates across Europe will lead to a surge in demand for efficient glucose monitoring and treatment, eventually generating demand for smart insulin pens to manage insulin among patients. Moreover, the rising preference for minimally invasive and convenient insulin delivery systems will also drive the demand for these pens.

Moreover, the Governments of various countries, backed by the EU, are making initiatives to reduce diabetes prevalence in the region. Various initiatives and programs are being developed by regulatory bodies in alignment with their objective, thus supporting the promotion of advanced treatment technologies such as smart insulin pens. Europe has a huge mass living with diabetes and is still undiagnosed. WHO stated that in 2023, around 3 people were living with diabetes and were undiagnosed. Similar undiagnosed populations represent a huge untapped market that can be targeted by the manufacturers of Insulin pens in the coming years.

Additionally, the country has seen significant growth in healthcare expenditure owing to the increased innovations, growing disposable income, and rising diabetic population. Europe’s healthcare expenditure on diabetes was USD 189.3 billion in 2021, which is anticipated to increase to USD 189.6 billion by 2030, as mentioned by the International Diabetes Federation's published data. Such an escalation in spending on diabetes illustrates the consciousness and awareness towards diabetes and innovative and cutting-edge healthcare services & solutions of the Europeans, causing a vast demand for the smart pens during the forecast period.

Also, compared with their traditional counterparts, smart insulin pens are advanced in terms of technology.  The smart ones can do a lot more than just injecting insulin, such as real-time dose tracking & logging, connectivity & data syncing, providing alerts & reminders, CGM & Digital Health Integration, and more. These capabilities are a primary reason for the growing adoption of smart insulin pens, and this trend is anticipated to continue in the forecast period.

Apart from the growth prospects of the market, it is anticipated to face growth challenges due to the higher price of smart insulin pens in comparison to traditional insulin pens due to the obvious fact that these pens are equipped with advanced technologies offering higher potential in comparison to the traditional pens, further states the research report, “Europe Smart Insulin Pens Market Analysis, 2025”.

Europe Smart Insulin Pens Market Segmentation Analysis

Type 1 Diabetes Segment Captures Major Market Share

Based on the application, the market is further bifurcated into Type 1 Diabetes and Type 2 Diabetes. The largest share in the market under the application category was held by type 1 diabetes. The dominating share held by T1D in 2024 was around 70% of the market. The prevalence of diabetes is accelerating in the region due to the unhealthy lifestyle, which includes improper and unhealthy diet, lack of exercise, and stress. Unhealthy eating habits are a major factor among children and adolescents in the occurrence of diabetes among this demographic. As stated by the WHO, Europe has the highest burden of type 1 diabetes globally.

The patients living with type 1 diabetes are required to take one or more dosages of insulin through any external delivery device. Insulin dosages are mandatory for T1D patients as their body either stops producing insulin or produce it in an insufficient quantity. The number of dosages could be 1 or more, depending on the patient’s diabetes levels, regular diet, and lifestyle. Intake of insulin through traditional methods like syringes is inconvenient and painful. Thus, consumers’ inclination is rising towards insulin pens as they are easy to carry, convenient in application, and are more accurate.

Germany Leads the Europe Smart Insulin Pens Industry

Germany holds the largest share of around 18% in the European Smart Insulin Pen Industry and projects considerable growth in the coming period. This growth in the country is owing to the considerable presence of diabetic patients and Germany's efforts towards the integration of digital technology in healthcare. Germany had the highest number of diabetic patients among all other countries in the region, as portrayed by the IDF Atlas report of 2021.

These pens can be easily incorporated into electronic health records (EHR) and telemedicine platforms, coinciding with Germany's vision for the digitalization of the healthcare sector. These technological capabilities of smart pens make them an attractive and useful alternative to many other insulin administration solutions.

The rising individual expenditures related to diabetes across the country will also provide further market growth. For instance, in a report by IDF Atlas, the country’s healthcare expenditure per capita related to diabetes was stated to be USD 6,660.7 million in 2021, which is further anticipated to reach USD 6,833.2 million in 2030.  As the adoption of these devices continues to grow, they are expected to play an increasingly significant role in improving diabetes management and patient outcomes in Germany, and will in turn increase the market share of the country in the forecasted period.

Competitive Landscape

With strategic initiatives such as mergers, collaborations, and acquisitions, the leading market companies, including Novo Nordisk A/s, Medtronic, Emperra GmbH, Pendiq, Eli Lilly and Company, and others, are looking forward to strengthening their market positions.

Key Questions Answered in the Research Report

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the region?
4. How has the industry been evolving in terms of geography & product adoption?
5. How has the competition been shaping up across various countries?
6. How have buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2020-30?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?